Overview
Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
Status:
Terminated
Terminated
Trial end date:
2011-03-01
2011-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
RATIONALE: Gefitinib may stop the growth of kidney cancer by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. PEG-interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of kidney cancer. Giving gefitinib together with PEG-interferon alfa-2b may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gefitinib together with PEG-interferon alfa-2b works in treating patients with unresectable or metastatic kidney cancer.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
California Cancer ConsortiumCollaborator:
National Cancer Institute (NCI)Treatments:
GefitinibInterferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2b
Criteria
DISEASE CHARACTERISTICS:- Histologically or cytologically confirmed renal cell carcinoma
- Metastatic or advanced/unresectable disease
- Measurable or nonmeasurable disease as defined by RECIST criteria
- No uncontrolled brain metastases
- Patients with adequately treated brain metastases who are not taking
anticonvulsants and corticosteroids may be eligible
PATIENT CHARACTERISTICS:
- Karnofsky performance status 60-100%
- Life expectancy ≥ 12 weeks
- WBC ≥ 3,500/mm³
- Platelet count ≥ 100,000/mm³
- Absolute granulocyte count ≥ 1,500/mm³
- Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 50 mL/min
- Bilirubin ≤ 1.5 mg/dL
- AST ≤ 2 times upper limit of normal (ULN)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other malignancy within the past 5 years except adequately treated basal cell or
squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or adequately
treated stage I or II cancer from which the patient is currently in complete remission
- No known severe hypersensitivity to gefitinib or its excipients
- No incomplete healing from previous oncologic or other major surgery
- No unresolved chronic toxicity > grade 2 from previous anticancer therapy (except
alopecia and anemia)
- No evidence of clinically active interstitial lung disease
- Patients with chronic stable radiographic changes who are asymptomatic are
eligible
- No evidence of severe or uncontrolled systemic disease (e.g., unstable or
uncompensated respiratory, cardiac, hepatic, or renal disease)
- No other significant clinical disorder or laboratory finding that would preclude study
participation
PRIOR CONCURRENT THERAPY:
- More than 30 days since prior nonapproved or investigational drugs
- More than 6 weeks since prior aldesleukin or interferon and recovered
- At least 3 weeks since prior radiotherapy
- No prior gefitinib
- Prior chemotherapy or biological therapy allowed
- Prior or concurrent bisphosphonate therapy for bone metastases allowed
- No concurrent phenytoin, carbamazepine, rifampin, barbiturates, phenobarbital, or
Hypericum perforatum (St. John's wort)
- No other concurrent agents specifically designed to inhibit the epidermal growth
factor receptor (EGFR)
- No concurrent radiotherapy to measurable lesions